Author

L.M. Spring

Observed names: L. M. Spring, L. Spring

Institutions: Harvard University, Massachusetts General Hospital, Mass General Brigham

Observed institutions: Harvard University, Massachusetts General Hospital, Mass General Brigham

OpenAlex ID: A5090731282

A Phase I Study of Adjuvant Niraparib Administered Concurrently with Postoperative Radiation Therapy in Patients with Localized Triple Negative Breast Cancer

2022 · J.C. Keenan, S.A. Dunn, et al. · International Journal of Radiation Oncology*Biology*Physics · 7

Abstract PD5-01: Personalized circulating tumor DNA (ctDNA) testing, intervention, and temporal dynamics in ER+/HER2- early-stage breast cancer (LEADER)

2026 · A. J. Medford, C. Scalise, et al. · Clinical Cancer Research · 2

Abstract PS3-11-04: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with HER2+ Breast Cancer - Results from the ATOP Study

2026 · R. A. Freedman, H. Heiling, et al. · Clinical Cancer Research · 1

336P Circulating tumor DNA detection in stage 1 HER2-positive and triple-negative breast cancer (SAFE-DE)

2025 · A.J. Medford, S. Harrison, et al. · Annals of Oncology · 1

Abstract PS2-07-02: Tissue-free epigenomic circulating tumor DNA (ctDNA) analysis pre- and post-surgery in early breast cancer: clinical features and prognostic utility

2026 · A. J. Medford, J. Knape, et al. · Clinical Cancer Research

135P Characteristics and dosing patterns of US patients diagnosed with HR+/HER2- early breast cancer initiating abemaciclib at a lower dose than the approved 150mg BID

2024 · L.M. Spring, W.G. Gathirua-Mwangi, et al. · ESMO Open

Works count: 6

Citation count: 11

H-index: 2

I10-index: